iBio, Inc. Form 10-Q Summary
Reporting period: Quarterly and nine-month periods ended March 31, 2015. The provided filing text identifies the report as a Form 10-Q filed May 15, 2015; it does not correspond to “2014 Q3” in the request metadata.
Business Context and Reporting Period
iBio is a biotechnology company commercializing plant-based protein expression technologies, including the iBioLaunch and iBioModulator platforms, and developing selected biopharmaceutical candidates. Its principal near-term objectives are securing licensing and collaboration arrangements and advancing IBIO-CFB03 for fibrotic diseases.
The company operates in one business segment. Its Brazilian subsidiary began operations during fiscal 2015, but generated no revenue during the reported periods. The filing presents unaudited condensed consolidated financial statements under U.S. GAAP.
Financial Performance and Position
| Metric | Three Months Ended March 31 | Nine Months Ended March 31 |
|---|---|---|
| Revenue | $349,000 in 2015; none in 2014 | $1.535 million in 2015; none in 2014 |
| Operating loss | $1.688 million in 2015; $1.294 million in 2014 | $4.770 million in 2015; $2.689 million in 2014 |
| Net loss | $1.677 million in 2015; $1.279 million in 2014 | $4.740 million in 2015; $2.524 million in 2014 |
| Loss per share | $0.02 basic and diluted loss | $0.07 basic and diluted loss |
- Revenue consisted of technology services for FioCruz’s yellow fever vaccine program. Related subcontractor research and development costs were substantially equal to revenue, so the activity generated no profit.
- Research and development expense was $815,000 for the quarter and $2.731 million for the nine months. General and administrative expense was $1.222 million for the quarter and $3.574 million for the nine months.
- Adjusted for prior-year Settlement Agreement credits, nine-month research and development and general and administrative spending increased by approximately $1.2 million and $624,000, respectively. Legal fees were a principal driver of higher general and administrative expense.
- Cash was $8.080 million at March 31, 2015, compared with $3.590 million at June 30, 2014. Total current assets were $9.044 million and total liabilities were $1.254 million.
- The company had no reported debt balance; liabilities consisted primarily of accounts payable, accrued expenses, and deferred revenue.
- Net cash used in operating activities was $3.518 million for the nine months. Investing activities used $152,000, while financing activities provided $8.169 million.
- Financing proceeds included $7.302 million from common-stock sales to Aspire Capital and $867,000 from warrant exercises.
- Accumulated deficit was $45.942 million at March 31, 2015. No income tax expense was recorded because the company maintained a valuation allowance against its deferred tax assets.
Material Changes Versus the Prior Comparable Period
- The company began recognizing revenue from the amended FioCruz/Fraunhofer arrangement, producing $349,000 in quarterly revenue and $1.535 million for the nine-month period versus no revenue in the prior-year periods.
- Quarterly net loss increased from $1.279 million to $1.677 million, and nine-month net loss increased from $2.524 million to $4.740 million.
- Prior-year operating expenses benefited from approximately $1.743 million of credits related to the 2013 Fraunhofer Settlement Agreement, including $1.041 million in research and development and $700,000 in general and administrative credits. The prior year also included a $122,000 interest-expense reversal.
- Common shares outstanding increased to approximately 74.1 million at March 31, 2015 from approximately 65.6 million at June 30, 2014. Weighted-average shares for the nine months increased to 69.9 million from 62.1 million.
- At March 31, 2015, approximately 9.7 million stock options and 6.6 million warrants could potentially dilute future earnings.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management estimated that $8.1 million of cash on hand would support operations through March 31, 2016, but stated that additional capital may be required for periods beyond that date.
- The company disclosed substantial doubt about its ability to continue as a going concern because of recurring losses, negative operating cash flow, limited resources, and dependence on additional financing. The financial statements were prepared assuming continued operations.
- On May 15, 2015, iBio entered into a new Aspire Capital agreement giving it the option to sell up to $15 million of common stock over three years, subject to contractual conditions and share limitations. The arrangement may result in substantial shareholder dilution.
- The prior $10 million Aspire facility was fully utilized by April 28, 2015. The related post-quarter-end sales included $2.698 million of proceeds and 2.684 million shares, which were not included in the March 31 financial statements.
- Under the Fraunhofer Settlement Agreement, iBio committed to engage Fraunhofer for at least $3 million of research and development work by December 31, 2015. Approximately $2.4 million had been incurred as of March 31, 2015.
- iBio filed litigation against Fraunhofer, its Center for Molecular Biotechnology, and an executive alleging contractual breaches and misuse or disclosure of proprietary intellectual property. The company also pursued claims against PlantForm and its president; the matters were consolidated in April 2015. The outcomes are not predictable.
- A putative securities class action was amended in April 2015 and names iBio and certain officers. The company filed a motion to dismiss in May 2015 and stated that neither the probability nor range of potential loss could be estimated.
- The company’s principal technology and intellectual property valuations, legal and contractual contingencies, research and development costs, and share-based compensation require significant management judgment.
Important Facts for Investors to Verify
- Whether the FioCruz yellow fever vaccine program will continue generating revenue and whether the associated services will remain economically neutral.
- The timing and terms of future equity issuances under the new Aspire Capital facility and the resulting dilution.
- Actual cash burn and whether available cash will support operations beyond the company’s stated March 31, 2016 estimate.
- Progress toward the $3 million Fraunhofer research commitment and the effect of the ongoing intellectual-property litigation on collaboration rights and operations.
- Clinical and regulatory progress for IBIO-CFB03 and other product candidates, which remained in preclinical or IND-enabling development.
- The outcome, insurance coverage, and potential financial exposure associated with the securities class action and other litigation.